Braidwell’s Bicycle Therapeutics BCYC Stock Holding History

Braidwell’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,289,872	Closed	-$25.9M	–	76
2023 Q3	$25.9M	Buy	+1,289,872	New	+$29.5M	0.82%	45

Other funds holding BCYC

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Braidwell's BCYC Position: Q4 2023 in Review

Braidwell sold out of Bicycle Therapeutics (BCYC) in Q4 2023, closing a stake of 1,289,872 shares — an estimated $25.9M sold.

Braidwell first reported a position in BCYC in Q3 2023 and held it in 1 quarter. The position peaked at $25.9M in Q3 2023. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

Braidwell reported no remaining Bicycle Therapeutics position as of Q4 2023 after selling out during the quarter.
Braidwell sold 1,289,872 Bicycle Therapeutics shares in Q4 2023, an estimated $25.9M.
Braidwell first reported a position in Bicycle Therapeutics in Q3 2023 and held it in 1 quarter.
Braidwell's Bicycle Therapeutics position peaked at $25.9M in Q3 2023.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.